Positive association between circulating 25-hydroxyvitamin D levels and prostate cancer risk: new findings from an updated meta-analysis

Xu, Yang; Shao, Xiaoping; Yao, Yacheng; Xu, Lijian; Chang, Liang; Jiang, Zhuojuan; Zhou, Lin

doi:10.1007/s00432-014-1706-3

Cited by 94 publications

(80 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Hence to hypothesize, VD inhibits the development of clinically significant, but not clini cally insignificant, prostate carcinoma [20]. On the contrary, studies provided by Xu et al revealed a significant 17% elevation in risk of prostate carcinoma for individuals with higher level of VD [21]. No such studies have been conducted in the Asian population and our study is the first of its kind in the Asian population.…”

Section: Discussionmentioning

confidence: 55%

Association of Vitamin D With Prostate Carcinoma: A Single Institutional Observational Study

Choubey¹,

Pipara²,

Mittal³

2017

World J Nephrol Urol

View full text Add to dashboard Cite

Background: Recent studies highlight a role for vitamin D (VD) in the growth and differentiation of various cell types. The biologically active form of vitamin D3 is 1,25-dihydroxyvitamin D3. Most cells of the body including prostate cells have vitamin D receptor (VDR) and VD metabolizing enzymes, and can respond to 1,25-VD. Literature supports multipronged effects of 1,25-VD in the prevention of prostate carcinoma development and progression. However, the relationship between prostate carcinoma and VD is still not entirely understood. There are no studies conducted on the association of VD and prostate carcinoma among the Asian population and our study is the first of its kind in literature and hence the need for the same.

show abstract

Section: Discussionmentioning

confidence: 55%

Association of Vitamin D With Prostate Carcinoma: A Single Institutional Observational Study

Choubey¹,

Pipara²,

Mittal³

2017

World J Nephrol Urol

View full text Add to dashboard Cite

show abstract

“…Prostate cancer is 1 malignancy for which the cumulative evidence points to a positive (i.e., harmful) association with vitamin D status (Table 1). A recent meta-analysis of 21 studies concluded that men with elevated serum levels of 25(OH)D had a higher risk of developing cancer of the prostate than did men with lower serum levels of 25(OH)D (21). Sixteen of the 21 studies showed positive associations, and the finding was similar when restricted to the prospectively conducted studies (odds ratio (OR) = 1.17, 95% confidence interval (CI): 1.08, 1.27) or to studies conducted in the United States and Europe (OR = 1.15, 95% CI: 1.03, 1.29; OR = 1.21, 95% CI: 1.04, 1.40, respectively).…”

Section: Blood Concentrations Of 25(oh)dmentioning

confidence: 99%

Vitamin D and Cancer Risk and Mortality: State of the Science, Gaps, and Challenges

Mondul

Weinstein

Layne

et al. 2017

Epidemiologic Reviews

164

133

View full text Add to dashboard Cite

There has been substantial enthusiasm recently regarding the potential role of vitamin D in the primary and secondary prevention of cancer. Laboratory studies demonstrate a range of anticarcinogenic effects for vitamin D compounds, but human studies have yielded little consistent evidence supporting a protective association. Higher circulating levels of vitamin D (i.e., 25-hydroxyvitamin D or 25(OH)D) appear to be associated with reduced risk of colorectal and bladder malignancies, but higher risk of prostate and possibly pancreatic cancers, with no clear association for most other organ sites examined. Despite there being no official institutional recommendations regarding the use of vitamin D supplements for cancer prevention, screenings for vitamin D deficiency and vitamin D supplement use have increased substantially over the past decade. These widespread practices demonstrate that population sociobehavioral changes are often adopted before scientifically well-informed policies and recommendations are available. This review critically examines the currently available epidemiologic literature regarding the associations between circulating 25(OH)D, vitamin D supplementation, and vitamin D-related genetic variation and cancer risk and mortality, with a particular emphasis on prospective studies. We identify several important gaps in our scientific knowledge that should be addressed in order to provide sufficient reproducible data to inform evidence-based recommendations related to optimal 25(OH)D concentrations (and any role for vitamin D supplementation) for the primary and secondary prevention of cancer. With few exceptions, such recommendations cannot be made at this time.

show abstract

“…For example, most studies show inverse associations for colorectal cancer, 11 whereas a recent meta-analysis showed higher vitamin D status increased the risk of prostate cancer. 13 Many nested case-control studies point to higher vitamin D being a risk factor for prostate cancer, including studies nested within the Alpha-Tocopherol, BetaCarotene (ATBC) 14 study and the Selenium and Vitamin E Cancer Prevention Trial. 15 Conversely, a nested casecontrol study from the Prostate Cancer Prevention Trial showed that higher levels of 25(OH)D reduce prostate cancer risk.…”

Section: Introductionmentioning

confidence: 99%

Metabolomics analysis of serum 25-hydroxy-vitamin D in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study

et al. 2016

View full text Add to dashboard Cite

Background: Vitamin D has been discussed in the context of cardiovascular disease, cancer, bone health and other outcomes. Epidemiological studies have reported on the importance of vitamin D in cancer prevention and treatment. The discovery of vitamin D-associated metabolites through agnostic metabolomics analyses offers a new approach for elucidating disease aetiology and health-related pathway identification. Methods: Baseline serum 25-hydroxy-vitamin D [25(OH)D] and 940 serum metabolites were measured in 392 men from eight nested cancer case-control studies in the AlphaTocopherol, Beta-Carotene Cancer Prevention Study of Finnish male smokers (aged 50-69 years). The metabolomic profiling was conducted using mass spectrometry. We used linear regression to estimate the standardized beta-coefficient as the effect metric for the associations between metabolites and 25(OH)D levels. Results: A majority of the metabolites associated with 25(OH)D were of lipid origin, including 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid (CMPF) [beta-estimate 0.38 per 1 standard deviation (SD) increment], stearoyl-arachidonoyl-glycerophosphoethanolamine (GPPE) (À0.38 per SD) and two essential fatty acids: eicosapentaenoate (EPA; 0.17 per SD) and docosahexaenoate (DHA; 0.13 per SD). Each of these lipid metabolites was associated with 25(OH)D at the principal components corrected P-value of 3.09 Â 10

show abstract

Positive association between circulating 25-hydroxyvitamin D levels and prostate cancer risk: new findings from an updated meta-analysis

Abstract: Our meta-analysis, for the first time, suggested significant positive relationship between high level of 25-hydroxyvitamin D and increased risk of prostate cancer, reminding us that more concern should be taken into account during assessing the effect of 25-hydroxyvitamin D.

Cited by 94 publications

References 51 publications

Association of Vitamin D With Prostate Carcinoma: A Single Institutional Observational Study

Association of Vitamin D With Prostate Carcinoma: A Single Institutional Observational Study

Vitamin D and Cancer Risk and Mortality: State of the Science, Gaps, and Challenges

Metabolomics analysis of serum 25-hydroxy-vitamin D in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study

Contact Info

Product

Resources

About